Actionable news
All posts from Actionable news
Actionable news in PGNX: Progenics Pharmaceuticals Inc.,

Progenics Pharmaceuticals: 777 Old Saw Mill River Road

The following excerpt is from the company's SEC filing.

Tarrytown, New York 10591

Fax: (914) 789-2817

(914) 789-2800

Phase 2 Dosimetry Data for Progenics' AZEDRA Presented at EANM

Congress 2015

Prospective Treatment Planning for High Dose Therapy Limits Radiation to Critical Organs -

– Progenics Pharmaceuticals, Inc., (Nasdaq: PGNX) today announced that data from its Phase 2 study of Azedra for the treatment of ultra-orphan indications pheochromocytoma and paraganglioma were highlighted during an oral presentation at the 28

Annual European Association of Nuclear Medicine (EANM) Congress being held in Hamburg, Germany.

Daniel Pryma, M.D., Associate Professor of Radiology and Radiation Oncology, Clinical Director of Nuclear Medicine and Molecular Imaging, University of Pennsylvania Perelman School of Medicine presented preliminary dosimetry data from the Phase 2 study in patients with iobenguane-avid metastatic and/or recurrent pheochromocytoma/paraganglioma. The study was designed to evaluate the efficacy and safety of two therapeutic doses of Azedra given 3 months apart, with dosimetric evaluation prior to the first therapeutic dose to ascertain avidity and tissue distribution. 44 patients had received a dosimetry dose before Molecular Insight suspended patient enrollment due to lack of funding.

"Prospective treatment planning via dosimetric evaluation for high-dose therapy is a critical component of radio-therapeutic development, serving as a safety check-point from which we can estimate the potential risk to critical organs," said Dr. Pryma. "This allows for dose adjustment for each individual if necessary, enhancing the safety profile of Azedra in this setting."

In this study, 44 patients underwent dosimetric evaluation, of which 41 (93.2%) demonstrated tumor avidity. 38 (86.4%) were eligible to receive up to 37 GBq based on dosimetry, while 6 (13.6%) required dose reduction based on pre-specified limits for the kidneys, liver, and lungs. Azedra was generally well tolerated with gastrointestinal and hematologic toxicity most frequently reported.

Dr. Pryma also presented updated preliminary long-term survival data from the first 41 patients dosed before enrollment in the trial was suspended in 2010. Seven of those patients had received one and 34 had received two therapeutic doses of Azedra. The...